Innate Pharma H1 2026: €19.6M Loss, Negative Equity, Going Concern Resolved by Sobi Deal and €30M Placement
IPHA sits 65% above its 52-week low of $1.17.
Summary
Innate Pharma's H1 2026 report shows a €19.6M net loss, cash down to €21.4M, and negative equity of €40.5M. The company states it would not have survived the next 12 months without the Sobi partnership and €30M placement completed in August, which now fund operations to Q1 2028.
Key Events · Earnings and Guidance · IPHA
-
Going Concern Resolved by August Financing
As of June 30, 2026, the Group would not have had sufficient resources for the next 12 months. The Sobi $75M upfront payment and €30M private placement completed in August now fund operations to Q1 2028.
-
H1 2026 Net Loss of €19.6M
Net loss narrowed from €21.3M in H1 2025, driven by a €3.6M reduction in R&D expenses and €2.0M reduction in G&A following restructuring.
-
Cash Position Deteriorated Sharply
Cash, cash equivalents and financial assets fell to €21.4M as of June 30, 2026, from €44.8M at December 31, 2025. Net cash was only €0.1M.
-
Negative Shareholders' Equity
Total shareholders' equity was negative €40.5M as of June 30, 2026, compared to negative €21.7M at year-end 2025.
Analysis · IPHA · Life Sciences
The half-year report lays bare how close Innate Pharma came to insolvency. Cash and financial assets had dwindled to €21.4M by June 30, 2026, down from €44.8M at year-end, while shareholders' equity sat at a negative €40.5M. The filing is explicit: without the Sobi partnership and the €30M private placement completed in August, the Group would not have had sufficient resources to fund operations for the next twelve months. Those two events—the $75M Sobi upfront payment and the €30M equity raise at €1.70 per share—pulled the company back from the brink, extending runway to Q1 2028. The going concern disclosure is the key new information here, quantifying just how precarious the situation was before the August financing events.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IPHA was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.7M. The 52-week trading range was $1.17 to $2.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.